We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Fate Therapeutics, Inc. (NASDAQ: FATE) today highlighted positive interim clinical data from the Company's FT516 and FT596 programs for patients with relapsed / refractory B-cell lymphoma.